marrow recovery refer, therefore, solely to the regression of leukaemic blast cells. By three weeks only 65 6% of the patients in the Concord trial and 67-5 % in the UKALL I trial but 804% in the UKALL II trial had less than 5% of blast cells in the marrow. A higher proportion of UKALL II marrow specimens, however, showed severely decreased cellularity at three weeks, though this finding was not sufficiently quantitative to be analysed further. At six and 13 weeks there was no significant difference between the bone marrow regression rates in the three trials.
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Discussion
The validity of comparing trials not carried out simultaneously is often called into question but it seems unlikely that this caused any serious bias in this instance. In particular there was no reason to suppose that the methods of measurement and management had significantly altered within the four years under study.
Our evidence shows that the addition of colaspase during the first week of the remission induction regimen of vincristine and prednisolone causes a significantly increased suppression of both normal and leukaemic cells in the bone marrow, as shown by the increased blast-cell regression and lower blood neutrophil and platelet counts. The induced neutropenia resulted in an increased liability to serious and fatal infections to which the immunosuppressive effect of colaspase (Maral et al., 1970) , the alteration of neutrophil function by asparagine depletion (Strauss et al., 1970; Skeel et al., 1971) , or an effect of colaspase on the gut mucosa might also have contributed. The clinical importance of the added period of thrombocytopenia is difficult to assess, since bleeding was largely prevented by platelet transfusion.
Colaspase could cause marrow depression either directly or by potentiating the myelotoxicity of vincristine. A potentiating effect might be mediated by the liver, since the hepatotoxicity of colaspase (Land et al., 1970; Pratt and Johnson, 1971) (World Health Organization, 1973) .
In Great Britain the reported prevalence of HBAg in patients admitted to hospital with hepatitis has varied between 4% (Ross and McMichael, 1970) and 40% (Cossart et al., 1969 We decided to determine the incidence of HBAg among all patients accepted as having viral hepatitis* within a defined area, whether or not they were admitted to hospital. At the same time we examined the epidemiology of viral hepatits with special reference to its distribution in the community, possible modes of spread, and factors affecting severity in relation to the presence of HBAg.
A 12-month pilot study was undertaken to assess the value of such an investigation. The most interesting feature of this study was a low incidence (14%) of HBAg in sporadic hepatitis in an urban area, which contrasted with previous reports from London (Cossart et al., 1969; Farrow et al., 1970 history of a febrile or gastrointestinal illness and dark urine followed by jaundice. In 15 (6%) cases, however, jaundice was not confirmed. Seven of these patients were detected as contacts of patients who were jaundiced because of viral hepatitis.
The patients were allocated to the following arbitrary epidemiological groups based on the history of the possible mode of exposure to infection: (a) Ingestion-definite close contact with another case of jaundice thought to be due to viral hepatitis between 15 and 60 days before the onset of symptoms; (b) parenteral-known history of skin puncture between 15 days and six months before the onset of symptoms; (c) unknownno known history of exposure to either ingestion or parenteral infection; (d) equivocal-history of exposure to both ingestion and parenteral infection within the relevant periods. This grouping seemed to be a reasonable device to gain more insight into the aetiological agents.
Methods
All patients on whom the field team received information were interviewed by the health visitor using a questionnaire developed during the pilot study. The visiting doctor made a clinical assessment and obtained blood for biochemical tests to support the diagnosis and for serological tests. Epidemiological data were collected at the time of the initial interview and were transferred to punch cards. The patients were seen initially about once a week for clinical assessment and collection of further blood samples and then less often until they had recovered both clinically and biochemically and until any antigenaemia had cleared.
Serum bilirubin (Malloy and Evelyn, 1937) , alkaline phosphatase (Marsh et al., 1959) , and alanine aminotransferase (Mohun and Cook, 1957) were measured by standard methods. The HBAg was detected by a sandwich-type radioimmunoassay technique (Ausria125) as previously used by Reed et al. (1973) , which combines the specificity of antigen-antibody reaction with the sensitivity of radioisotope detection and is now accepted as the most sensitive technique available (World Health Organization, 1973 In the parenteral group four of the 10 patients who had a nontherapeutic skin puncture were HBAg positive whereas 14 (21%) of the 67 whose parenteral exposure was therapeutic showed the antigen. Four HBAg-negative patients had both therapeutic and non-therapeutic exposures. In the non-therapeutic group there were four drug addicts, two of whom were HBAg positive. Four had been tattooed, of whom two were positive.
There were more than five times as many men (27) as women (five) with the HBAg though the overall ratio of male (129) to female (86) patients tested was 1-5:1 (table II) . Nearly half the males were in the parenteral group. The unknown group contained about equal numbers of males and females but the HBAg was found only in the males.
In the 20-39 age group there were nearly twice as many men as women (table III) , and 19 of the 62 men (31 %) were HBAg positive compared with only four of the 35 women (11 %). This age group contributed two thirds (23 out of 32) of all the HBAgpositive patients. All but two of these antigen-positive patients fell into the parenteral or unknown groups (table I) .
Half the patients in the ingestion and equivocal groups were under the age of 15 whereas only one in 7 of the parenteral and unknown groups were of this age (see table I Previous reports from West London (Cossart et al., 1969 , Farrow et al., 1970 suggested that the prevalence of HBAg in sporadic hepatitis in the United Kingdom was in the region of 30-40%. Both studies were of patients admitted to hospital, however, whereas we attempted to investigate all patients developing this illness irrespective of their place of care. Our data suggested that the higher prevalence of HBAg in hospital patients might be due to the larger number of adult males admitted.
The pilot study had shown the vital importance of full collaboration with the general practitioners and they were therefore involved in the three-year survey through discussions at meetings held for this purpose both before and during the survey. A domiciliary diagnostic service was provided on all patients referred by family doctors, who reciprocated by informing the survey team of possible preicteric cases and with early notifications. As a result of this collaboration most sera were taken early in the illness.
The proportion of positive results showed no significant difference throughout the first four weeks, nor was there a significant difference between the mean number of tests in the HBAg positive and negative patients. The proportion of patients tested in the two groups was the same. Though we cannot exclude the possibility of clearance of the antigen before the onset of jaundice other studies suggest that this is unusual (Krugman and Giles, 1970) .
The 20-39 age groups accounted for 19 of the 27 positive men and all but one of the five positive women (table III) . The predominance of young adults was not explained by drug addiction, because only four patients in the whole survey admitted to this practice. The possibility of venereal transfer has been raised by Mirick and Shank (1959) , Hersh et al. (1971), and Fulford et al. (1973) .
The preponderance of males has been noted previously (reviewed by Zuckerman, 1972) and may be due to a sex difference in susceptibility to infection. It is of interest that nearly half the HBAg positive patients in this survey were men with a history of parenteral exposure though most of these exposures involved the use of disposable equipment -for instance, in vaccinations, inoculations, and dental local anaesthetics. One third of the children (under 15 years) had had a skin puncture under similar conditions and none of them was HBAg positive.
Fewer children than adults were tested for (Anderson and Arner, 1972) . We report here a comparison with LVP showing the more prolonged action of DDAVP, it seffective control of a wide range of cases of vasopressin sensitive diabetes insipidus on a twice-daily intranasal regimen, and its potential usefulness in controlling such cases by single daily injections when necessary.
Patients
Altogether 11 patients were studied (table I). All had previously been investigated and diagnosed as having vasopressinsensitive diabetes insipidus either alone or with associated pituitary lesions. None of the patients were satisfied with their immediate previous therapy (talble I). On their current regimens all had some persisting symptoms of mild thirst, polyuria, and nocturia. Six patients had had trials with either clofibrate or chlorothiazide or carbamazepine carried out by us or at other hospitals. Five patients previously treated with chlorpropamide 250-500 mg daily had had to have the drug withdrawn or the dosage reduced because of hypoglycaemia, and one patient had had an "Antabuse" effect with alcohol. Five patients were maintained on vasopressin tannate in oil (5 IU intramuscularly on alternate days) with or without LVP nasal spray supplementation. One patient (case 2) who had been maintained on posterior pituitary nasal snuff for 10 years had not had an undisturbed night's sleep or been free of rhinitis throughout that time.
Method
Previous therapy was discontinued (five days for those on chlorpropanide and one to three days for those receiving vasopressin preparations). Thereafter all the patients' 24-hour urine volumes were measured, initially when off all previous treatment and later while on maintenance intranasal DDAVP.
Before establishing the patients on maintenance therapy a series of acute studies were performed of their diuretic response both uncontrolled and after LVP or DDAVP, either as inpatients or as outpatients. Firstly, a full diuresis was ensured by an oral water load of 20 ml/kg given over 30 minutes, after which they were urged to drink an amount at
